International perspectives on the cost-effectiveness of tandem mass spectrometry for rare metabolic conditions

Health Policy

Volumn 89, Issue 3, 2009, Pages 252-260

  Norman, Richard ^a   Haas, Marion ^a   Wilcken, Bridget ^b,c  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cost effectiveness; Health economics; Metabolism; Review; Tandem mass spectrometry

Indexed keywords

COST-BENEFIT ANALYSIS; INTERNATIONALITY; METABOLIC DISEASES; RARE DISEASES; TANDEM MASS SPECTROMETRY;

EID: 60849136588     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2008.08.003     Document Type: Review

References (31)

1. Wilcken B., Wiley V., Hammond J., and Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. New England Journal of Medicine 348 (2003) 2304-2312
2. Wilcken B., Haas M., Joy P., Wiley V., Chaplin M., Black C., et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 369 (2007) 37-42
3. Haas M., Chaplin M., Joy P., Wiley V., Black C., and Wilcken B. Healthcare use and costs of medium-chain acyl-CoA dehydrogenase deficiency in Australia: screening versus no screening. Journal of Pediatrics 151 (2007) 121-6, 26 e1
4. Seymour C.A., Thomason M.J., Chalmers R.A., Addison G.M., Bain M.D., Cockburn F., et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technology Assessment 1 (1997) i-iv, 1-95
5. Autti-Rämö I., Makela M., Sintonen H., Koskinen H., Laajalahti L., Halila R., et al. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland. Acta Paediatrica 94 (2005) 1126-1136
6. Schoen E.J., Baker J.C., Colby C.J., and To T.T. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics 110 (2002) 781-786
7. Carroll A.E., and Downs S.M. Comprehensive cost-utility analysis of newborn screening strategies. Pediatrics 117 (2006) S287-S295
8. Tran K., Banerjee S., Li H., Noorani H.Z., Mensinkai S., and Dooley K. Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. Clinical Biochemistry 40 (2007) 235-241
9. Insinga R.P., Laessig R.H., and Hoffman G.L. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. Journal of Pediatrics 141 (2002) 524-531
10. Cipriano L.E., Rupar C.A., and Zaric G.S. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. Value Health 10 (2007) 83-97
11. Mudd S.H., Skovby F., Levy H.L., Pettigrew K.D., Wilcken B., Pyeritz R.E., et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. American Journal of Human Genetics 37 (1985) 1-31
12. Venditti L.N., Venditti C.P., Berry G.T., Kaplan P.B., Kaye E.M., Glick H., et al. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics 112 (2003) 1005-1015
13. Bittles A.H., Petterson B.A., Sullivan S.G., Hussain R., Glasson E.J., and Montgomery P.D. The influence of intellectual disability on life expectancy. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57 (2002) M470-M472
14. Pandor A., Eastham J., Beverley C., Chilcott J., and Paisley S. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technology Assessment 8 (2004) iii, 1-121
15. van der Hilst C.S., Derks T.G., Reijngoud D.J., Smit G.P., and TenVergert E.M. Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands. Journal of Pediatrics 151 (2007) 115-20, 20 e1-3
16. Feuchtbaum L., and Cunningham G. Economic evaluation of tandem mass spectrometry screening in California. Pediatrics 117 (2006) S280-S286
17. Bennett J.E., Sumner II W., Downs S.M., and Jaffe D.M. Parents' utilities for outcomes of occult bacteremia. Archives of Pediatrics & Adolescent Medicine 154 (2000) 43-48
18. Saigal S., Feeny D., Rosenbaum P., Furlong W., Burrows E., and Stoskopf B. Self-perceived health status and health-related quality of life of extremely low-birth-weight infants at adolescence. Journal of the American Medical Association 276 (1996) 453-459
19. Neumann P.J., Sandberg E.A., Araki S.S., Kuntz K.M., Feeny D., and Weinstein M.C. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Medical Decision Making 20 (2000) 413-422
20. Scriver C. The metabolic and molecular bases of inherited disease. 8th ed. (2001), McGraw-Hill, New York, NY
21. Wolf B., Spencer R., and Gleason T. Hearing loss is a common feature of symptomatic children with profound biotinidase deficiency. Journal of Pediatrics 140 (2002) 242-246
22. PriceWaterhouseCoopers. Newborn screening programs: an overview of cost and financing. New York, NY; 2002.
23. Pandor A., Eastham J., Chilcott J., Paisley S., and Beverley C. Economics of tandem mass spectrometry screening of neonatal inherited disorders. International Journal of Technology Assessment in Health Care 22 (2006) 321-326
24. Pollitt R.J., Green A., McCabe C.J., Booth A., Cooper N.J., Leonard J.V., et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technology Assessment 1 (1997) i-iv, 1-202
25. Schulze A., Lindner M., Kohlmuller D., Olgemoller K., Mayatepek E., and Hoffmann G.F. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 111 (2003) 1399-1406
26. Derks T.G., Reijngoud D.J., Waterham H.R., Gerver W.J., van den Berg M.P., Sauer P.J., et al. The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: clinical presentation and outcome. Journal of Pediatrics 148 (2006) 665-670
27. BeechamJ, O'Neill T., and Goodman R. Supporting young adults with hemiplegia: services and costs. Health & Social Care in the Community 9 (2001) 51-59
28. Lord J., Thomason M.J., Littlejohns P., Chalmers R.A., Bain M.D., Addison G.M., et al. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria. Journal of Epidemiology and Community Health 53 (1999) 179-186
29. Koopmanschap M.A., Rutten F.F., van Ineveld B.M., and van Roijen L. The friction cost method for measuring indirect costs of disease. Journal of Health Economics 14 (1995) 171-189
30. Stevens K. Working with children to develop dimensions for a preference based generic paediatric health related quality of life measure. Health Economics and Decision Science Discussion Paper Series: ScHARR, University of Sheffield, 2008.
31. Radhakrishnan M., van Gool K., Hall J., Delatycki M., and Massie J. Economic evaluation of cystic fibrosis screening: a review of the literature. Health Policy 85 (2008) 133-147